Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
Nrf2 inhibition resulted in repression of HER2-AKT/ERK1/2 signaling and sensitizes SK-OV-3 cells to trastuzumab treatment. (a) The level of p-HER2, p-AKT, and p-ERK1/2 were determined after treatment with Nrf2-targeted siRNA or scramble siRNA for 36 h. (b) Cell viability was monitored after trastuzumab (50 μg/mL) incubation for 24 h in scramble siRNA or Nrf2 siRNA-transfected cells. Cells were transfected with scramble siRNA or Nrf2 siRNA using Lipofectamine 2000 (Invitrogen) according to the supplier’s instruction. Data show the (three independent experiments). ;.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.